CLINICAL TRIAL OF A BETA-RECEPTOR BLOCKING AGENT (LB 46) IN MIGRAINE PROPHYLAXIS

Publisher Website
Google Scholar
Abstract
Twenty‐four patients were treated with a beta‐blocking agent (Viskén, LB 46 Sandoz) and placebo in double‐blind study. The dosage of Viskén was 15 mg in 11 patients and 7.5 mg in 13 patients, and each remedy was taken for 4 weeks with an interposed 3‐week “wash‐out” period. There was generally no definite change in migraine attack‐frequency or pattern during Viskén medication. Three patients, however, had a remarkably reduced number of attacks on Viskén. This reduction may or may not have been due to Viskén.

This publication has 4 references indexed in Scilit: